GlassScriptPhysician profile
Raza Zaidi
NPI 1093277162
$1,666.34
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $209 · 2023: $582 · 2024: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $282.06 | 2023-2024 | Rinvoq |
| Alexion Pharmaceuticals, INC. | $274.37 | 2023-2024 | Strensiq |
| Ucb, INC. | $180.49 | 2023-2024 | Cimzia |
| Amgen INC. | $174.92 | 2024 | Tavneos, Prolia, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.66 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $140.98 | 2023-2024 | Saphnelo |
| Horizon Therapeutics Plc | $101.54 | 2022 | |
| Sanofi-Aventis U.S. LLC | $91.99 | 2022 | |
| Aurinia Pharma U.S., INC. | $78.57 | 2023-2024 | Lupkynis |
| Genzyme Corporation | $50.29 | 2023-2024 | |
| Sobi, INC | $36.39 | 2022-2024 | |
| Fresenius Kabi USA, LLC | $31.01 | 2023-2024 | Idacio |
| Pfizer INC. | $28.15 | 2024 | |
| Mallinckrodt Hospital Products INC. | $22.30 | 2024 | Acthar |
| Octapharma USA, INC. | $14.62 | 2023 | Octagam Immune Globulin (Human) |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raza Zaidi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.